AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29464587
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day lansoprazole
Trial: 27306921
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen treatment (specific dosage and duration not available)
Trial: 25281675
Drug: Traditional preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional preparation methods
Trial: 20920044
Drug: intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intensive insulin therapy (IIT)
Trial: 18040529
Drug: Tiotropium inhalation
RxNorm normalized name: Tiotropium Inhalation Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium inhalation
Trial: 2287555
Drug: Tourniquet inflation
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tourniquet inflation at 5 minutes after cefazolin administration
Trial: 2287555
Drug: Tourniquet inflation
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tourniquet inflation at 2 minutes after cefazolin administration
Trial: 2287555
Drug: Tourniquet inflation
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tourniquet inflation at 1 minute after cefazolin administration
Trial: 6973989
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg fluproquazone
Trial: 28118533
Drug: Subcutaneous belimumab
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous belimumab 200 mg weekly
Trial: 23406311
Drug: Preoperative carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative carbohydrate drinks and postoperative polymeric supplement drinks
Trial: 19703126
Drug: DTPa2 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa2 and DTPa3 vaccines
Trial: 19703126
Drug: IgG anti-Fim2/3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG anti-Fim2/3 levels > or =5 EU/ml
Trial: 11151742
Drug: Caffeine 2.1
RxNorm normalized name: caffeine 2.17 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 2.1 mg kg‐1 body weight (low dose)
Trial: 11151742
Drug: Caffeine 4.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 4.3 mg kg‐1 body weight (medium dose)
Trial: 11151742
Drug: Caffeine 8.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 8.6 mg kg‐1 body weight (high dose)
Trial: 2871783
Drug: Bevantolol 200
RxNorm normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevantolol 200 to 400 mg/day
Trial: 29210953
Drug: Citrulline Malate
RxNorm normalized name: CITRULLINE MALATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrulline Malate (CM) 8 g
Trial: 22998687
Drug: Esomeprazole (ESO)
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole (ESO) treatment for 5 years
Trial: 9457819
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy (HFX RT) with a thoracic spinal cord dose of 50.4 Gy given via 1.2 Gy b.i.d. fractionation
Trial: 2612558
Drug: Sustained-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release verapamil 360 mg at 22.00 h
Trial: 2612558
Drug: Sustained-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release verapamil 360 mg at 08.00 h
Trial: 2612558
Drug: Sustained-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release verapamil 360 mg at night (24.00 h-06.00 h)
Trial: 28981543
Drug: Daily 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 4% chlorhexidine care
Trial: 25939018
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Processing Therapy (CPT-C)
Trial: 16261517
Drug: Meta050 (440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meta050 (440 mg three times a day for 4 weeks, then 880 mg twice a day for 4 weeks)
Trial: 12072677
Drug: Coupled plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coupled plasma filtration adsorption plus hemodialysis (treatment A)
Trial: 12072677
Drug: Continuous venovenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous venovenous hemodiafiltration (treatment B)
Trial: 2224694
Drug: High-dose zidovudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose zidovudine therapy
Trial: 2224694
Drug: Low-dose zidovudine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose zidovudine therapy
Trial: 27393080
Drug: DHEA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (50 mg/day orally) with EE/LNG
Trial: 27393080
Drug: DHEA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (50 mg/day orally) with EE/DRSP
Trial: 23111852
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with fosinopril and pravastatin
Trial: 12039422
Drug: Riluzole 50mg
RxNorm normalized name: RILUZOLE 50MG TAB
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riluzole 50mg capsules orally, taken twice daily
Trial: 7781667
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment in 108 NIDDM patients with Lp(a) concentration < 300 mgL-1
Trial: 7781667
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment in subjects with elevated Lp(a) concentrations (> 300 mgL-1)
Trial: 2202462
Drug: Total body
RxNorm normalized name: Total Body Massager Item
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total body irradiation followed by 12 courses of high dose cytosine arabinoside (Ara‐C)
Trial: 38705
Drug: Intravenous dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose of 10 mg of metopimazine, three times D-1, for two days
Trial: 38705
Drug: Identically administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically administered placebo
Trial: 31009289
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2 mg tolterodine and 9 mg pilocarpine
Trial: 31009289
Drug: Tolterodine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine monotherapy (2 mg twice daily)
Trial: 30341276
Drug: Exposure-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based cognitive behaviour therapy (CBT) for anxiety disorders, 4 weekly sessions
Trial: 30341276
Drug: Exposure-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based cognitive behaviour therapy (CBT)
Trial: 27875537
Drug: L-tryptophan (0.52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (0.52 g and 1.56 g)
Trial: 27875537
Drug: L-tryptophan (1.56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (1.56 g)
Trial: 27875537
Drug: L-tryptophan and
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tryptophan and L-leucine
Trial: 27875537
Drug: Control (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (75 g glucose and 300 mL tap water)
Trial: 20369718
Drug: dichlorobis (N1‐dichloromethyl‐3,5‐dimethylpyrazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dichlorobis (N1‐dichloromethyl‐3,5‐dimethylpyrazole, copper (II) compound
Trial: 20369718
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment with the copper (II) compound)
Trial: 17395047
Drug: Candesartan (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (titrated to 32 mg once per day)
Trial: 15620485
Drug: Avanta implants
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Avanta implants
Trial: 375958
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Atenolol and Chlorthalidone
Trial: 375958
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy vs Placebo
Trial: 29329168
Drug: MenABCWY booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenABCWY booster dose
Trial: 24139668
Drug: Guided Experiential
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Experiential Learning (GEL)
Trial: 6367882
Drug: Post-operative radiotherapy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative radiotherapy (routine dose)
Trial: 6367882
Drug: Higher dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dosage (more than 1510 ret)
Trial: 6367882
Drug: Increased radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased radiotherapy dosage
Trial: 30053018
Drug: CPE isolates
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPE isolates identified from rectal swabs
Trial: 30053018
Drug: Carbapenemase characterization
RxNorm normalized name: Carbapenem
DrugBank: Carbapenem (DB18912)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbapenemase characterization and antibiotic susceptibility testing
Trial: 21084546
Drug: Hydro Acoustic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydro Acoustic Therapy (HAT)
Trial: 15805860
Drug: Control (ND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (ND before adjuvant therapy)
Trial: 10756363
Drug: Aprotinin (pump-prime-only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (pump-prime-only dose)
Trial: 10756363
Drug: No aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No aprotinin treatment (control)
Trial: 31124600
Drug: Perioperative antibiotic
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative antibiotic prophylaxis (PAP)
Trial: 31124600
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of PAP parenterally
Trial: 29186175
Drug: Oral vocabulary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vocabulary training program (definition method)
Trial: 29186175
Drug: Oral vocabulary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vocabulary training program (context method)
Trial: 17723127
Drug: Nadroparin 2850
RxNorm normalized name: Nadroparine
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin 2850 antifactor Xa units once daily for 3 weeks
Trial: 11719833
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose Bay 27‐9955 200 mg
Trial: 11719833
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose Bay 27‐9955 70 mg
Trial: 9604731
Drug: Piroxicam-FDDF (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam-FDDF (40 mg)
Trial: 2882607
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (550 mg)
Trial: 2899196
Drug: NCDDP promotion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NCDDP promotion of better treatment
Trial: 20166432
Drug: Cefteram pivoxil
RxNorm normalized name: cefteram pivoxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefteram pivoxil (test preparation)
Trial: 20166432
Drug: Cefteram pivoxil
RxNorm normalized name: cefteram pivoxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefteram pivoxil (reference preparation)
Trial: 15585778
Drug: cis‐9,trans‐11 CLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis‐9,trans‐11 CLA (0.59, 1.19, and 2.38 g/d)
Trial: 15585778
Drug: trans‐10,cis‐12 CLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trans‐10,cis‐12 CLA (0.63, 1.26, and 2.52 g/d)
Trial: 11745270
Drug: Protocol A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A: Twice-daily TBI (1.7 Gy for 3 days, total 10.2 Gy)
Trial: 11745270
Drug: Protocol B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B: Once-daily TBI (3 Gy for 4 days, total 12 Gy)
Trial: 8238222
Drug: 5-fluorouracil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (50 mg/ml for five minutes)
Trial: 3608729
Drug: Sequential aspartate
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential aspartate aminotransferase measurement followed by CCA
Trial: 28222649
Drug: Topical washing
RxNorm normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical washing with tranexamic acid
Trial: 21816223
Drug: Broccoli sprouts
RxNorm normalized name: broccoli sprout extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli sprouts (40 g)
Trial: 21816223
Drug: Broccoli supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli supplement (6 pills)
Trial: 21816223
Drug: Placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills (negative control)
Trial: 17684633
Drug: Tetanus control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus control vaccine
Trial: 12074614
Drug: Hyaluronidase injection
RxNorm normalized name: hyaluronidase Injection
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyaluronidase injection and aspiration
Trial: 9501748
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (SSRI), paroxetine, 20 mg/day
Trial: 2244675
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation through the nose from a pressurized aerosol attached to a spacer device
Trial: 666948
Drug: L(‐)‐bupivacaine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L(‐)‐bupivacaine at 7.69 mmol/l
Trial: 666948
Drug: D(+)‐bupivacaine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D(+)‐bupivacaine at 7.69 mmol/l
Trial: 666948
Drug: L(‐)‐bupivacaine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L(‐)‐bupivacaine at 0.48 mmol/l
Trial: 666948
Drug: L(‐)‐bupivacaine from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L(‐)‐bupivacaine from 0.48‐3.84 mmol/l
Trial: 666948
Drug: D(+)‐bupivacaine from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D(+)‐bupivacaine from 0.48‐3.84 mmol/l
Trial: 31023759
Drug: Amoxicillin-clavulanate (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (80 mg/kg/day, maximum 980 mg of amoxicillin in two-divided doses) for 8 days
Trial: 31023759
Drug: Placebo (equal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equal volume and dosing frequency) for 8 days
Trial: 28953325
Drug: Second-line protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line protease inhibitor (PI)-based ART
Trial: 21508140
Drug: Anakinra 150
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra 150 mg sc once daily for 4 weeks
Trial: 19080072
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg (Group 1, n=153)
Trial: 19080072
Drug: Enalapril maleate
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril maleate and folic acid tablet at the ratio of 10/0.4 (Group 2, n=151)
Trial: 19080072
Drug: Enalapril maleate
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril maleate and folic acid tablet at the ratio of 10/0.8 (Group 3, n=152)
Trial: 16571963
Drug: Closed-loop propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Closed-loop propofol target control infusion
Trial: 16571963
Drug: Manual propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual propofol target control infusion
Trial: 12722174
Drug: Mirtazapine 45
RxNorm normalized name: mirtazapine 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 45 mg per day for 2 weeks
Trial: 12722174
Drug: Mirtazapine 45
RxNorm normalized name: mirtazapine 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 45 mg per day
Trial: 7939938
Drug: Chloroquine 300
RxNorm normalized name: chloroquine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 300 mg base weekly plus Fansidar 1 tab/week (group 3)
Trial: 3521245
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (700,000 units)
Trial: 24796043
Drug: Staging acupoint
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staging acupoint embedment therapy, applied twice during the menstrual cycle (3 days before menstruation and during the 12th-14th days of menstruation) using specific acupoints.
Trial: 24796043
Drug: Fenbid, 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenbid, 0.3 g orally, twice a day, starting 3 days before menstruation until pain relief, for 3 menstrual cycles.
Trial: 24796043
Drug: Staging acupoint
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staging acupoint embedment therapy
Trial: 24490264
Drug: Oral high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral high-dose multivitamins and multiminerals
Trial: 21649815
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bleaching agents (glycolic acid, kojic acid, lipohydroxyacid, and Vitreoscilla extract) applied daily for 3 months
Trial: 18294022
Drug: Active transcranial
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transcranial magnetic stimulation (TMS) administered 5 times per week at 10 pulses per second, at 120% of motor threshold, for a total of 3000 pulses/session.
Trial: 17197740
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy (platinum-based)
Trial: 9372379
Drug: Parenteral support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral support (isonitrogenous isocaloric)
Trial: 1589282
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy for acute spinal cord injury
Trial: 10341115
Drug: Physostigmine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine administered orally every 2 hr, six times per day for 10 days
Trial: 7745021
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist treatment (discontinued after 4 and 10 months)
Trial: 1904090
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose and total parenteral nutrition with insulin
Trial: 1904090
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous therapy alone
Trial: 7440748
Drug: Child modulator
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child modulator intervention for a 6‐month period
Trial: 30657228
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to a paediatric specialist for treatment planning
Trial: 30657228
Drug: Restoration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restoration of cFPM including root canal treatment
Trial: 27673579
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (HD-Ara-C)
Trial: 22289530
Drug: Remifentanil 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 6 ng/ml
Trial: 22289530
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Remifentanil 0 ng/ml)